Wild-Type p53 controls the level of fibronectin expression in breast cancer cells

Daeun You, Seung Pil Jung, Yisun Jeong, Soo Youn Bae, Sangmin Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aberrant fibronectin (FN) expression is associated with poor prognosis, cell adhesion, and cell motility in a variety of cancer cells. In this study, we investigated the relationship between p53 and FN expression in breast cancer cells. Basal FN expression was significantly decreased by treatment with the p53 activator III, RITA, in MCF7 breast cancer cells with wild-Type p53. In addition, overexpression of wild-Type p53 markedly decreased the level of FN expression in p53-mutant breast cancer cells. To examine the mechanism underlying the relationship between p53 and FN expression, we treated MCF7 breast cancer cells with the tumor promoter TPA (12-O-Tetradecanoylphorbol-13-Acetate). Our results showed that basal FN expression was increased by TPA treatment in a time-dependent manner. In contrast, the level of p53 expression was decreased by TPA treatment. However, the expression of FN and p53 was not altered by TPA in p53-mutant breast cancer cells. Furthermore, the alterations in FN and p53 expression in response to TPA were prevented by a specific MEK inhibitor, UO126. Finally, we demonstrated that TPA triggers degradation of p53 through the proteasomal pathway in MCF7 cells. TPA-induced FN expression was decreased by the proteasome inhibitor MG132. Under the same condition, p53 protein expression, but not mRNA expression, was reversed by MG132. Taken together, our data demonstrate that the level of FN expression is associated with the status and expression of p53 in breast cancer cells.

Original languageEnglish
Pages (from-to)2551-2557
Number of pages7
JournalOncology Reports
Volume38
Issue number4
DOIs
Publication statusPublished - 2017 Oct 1

Fingerprint

Fibronectins
Tetradecanoylphorbol Acetate
Breast Neoplasms
Proteasome Inhibitors
Mitogen-Activated Protein Kinase Kinases
MCF-7 Cells
Cell Adhesion
Carcinogens
Cell Movement
Messenger RNA

Keywords

  • ERK
  • Fibronectin
  • MEK
  • P53
  • Proteasomal degradation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wild-Type p53 controls the level of fibronectin expression in breast cancer cells. / You, Daeun; Jung, Seung Pil; Jeong, Yisun; Bae, Soo Youn; Kim, Sangmin.

In: Oncology Reports, Vol. 38, No. 4, 01.10.2017, p. 2551-2557.

Research output: Contribution to journalArticle

You, Daeun ; Jung, Seung Pil ; Jeong, Yisun ; Bae, Soo Youn ; Kim, Sangmin. / Wild-Type p53 controls the level of fibronectin expression in breast cancer cells. In: Oncology Reports. 2017 ; Vol. 38, No. 4. pp. 2551-2557.
@article{77c0a71c306b4e3dad9a1c8d2e05e6b9,
title = "Wild-Type p53 controls the level of fibronectin expression in breast cancer cells",
abstract = "Aberrant fibronectin (FN) expression is associated with poor prognosis, cell adhesion, and cell motility in a variety of cancer cells. In this study, we investigated the relationship between p53 and FN expression in breast cancer cells. Basal FN expression was significantly decreased by treatment with the p53 activator III, RITA, in MCF7 breast cancer cells with wild-Type p53. In addition, overexpression of wild-Type p53 markedly decreased the level of FN expression in p53-mutant breast cancer cells. To examine the mechanism underlying the relationship between p53 and FN expression, we treated MCF7 breast cancer cells with the tumor promoter TPA (12-O-Tetradecanoylphorbol-13-Acetate). Our results showed that basal FN expression was increased by TPA treatment in a time-dependent manner. In contrast, the level of p53 expression was decreased by TPA treatment. However, the expression of FN and p53 was not altered by TPA in p53-mutant breast cancer cells. Furthermore, the alterations in FN and p53 expression in response to TPA were prevented by a specific MEK inhibitor, UO126. Finally, we demonstrated that TPA triggers degradation of p53 through the proteasomal pathway in MCF7 cells. TPA-induced FN expression was decreased by the proteasome inhibitor MG132. Under the same condition, p53 protein expression, but not mRNA expression, was reversed by MG132. Taken together, our data demonstrate that the level of FN expression is associated with the status and expression of p53 in breast cancer cells.",
keywords = "ERK, Fibronectin, MEK, P53, Proteasomal degradation",
author = "Daeun You and Jung, {Seung Pil} and Yisun Jeong and Bae, {Soo Youn} and Sangmin Kim",
year = "2017",
month = "10",
day = "1",
doi = "10.3892/or.2017.5860",
language = "English",
volume = "38",
pages = "2551--2557",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Wild-Type p53 controls the level of fibronectin expression in breast cancer cells

AU - You, Daeun

AU - Jung, Seung Pil

AU - Jeong, Yisun

AU - Bae, Soo Youn

AU - Kim, Sangmin

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Aberrant fibronectin (FN) expression is associated with poor prognosis, cell adhesion, and cell motility in a variety of cancer cells. In this study, we investigated the relationship between p53 and FN expression in breast cancer cells. Basal FN expression was significantly decreased by treatment with the p53 activator III, RITA, in MCF7 breast cancer cells with wild-Type p53. In addition, overexpression of wild-Type p53 markedly decreased the level of FN expression in p53-mutant breast cancer cells. To examine the mechanism underlying the relationship between p53 and FN expression, we treated MCF7 breast cancer cells with the tumor promoter TPA (12-O-Tetradecanoylphorbol-13-Acetate). Our results showed that basal FN expression was increased by TPA treatment in a time-dependent manner. In contrast, the level of p53 expression was decreased by TPA treatment. However, the expression of FN and p53 was not altered by TPA in p53-mutant breast cancer cells. Furthermore, the alterations in FN and p53 expression in response to TPA were prevented by a specific MEK inhibitor, UO126. Finally, we demonstrated that TPA triggers degradation of p53 through the proteasomal pathway in MCF7 cells. TPA-induced FN expression was decreased by the proteasome inhibitor MG132. Under the same condition, p53 protein expression, but not mRNA expression, was reversed by MG132. Taken together, our data demonstrate that the level of FN expression is associated with the status and expression of p53 in breast cancer cells.

AB - Aberrant fibronectin (FN) expression is associated with poor prognosis, cell adhesion, and cell motility in a variety of cancer cells. In this study, we investigated the relationship between p53 and FN expression in breast cancer cells. Basal FN expression was significantly decreased by treatment with the p53 activator III, RITA, in MCF7 breast cancer cells with wild-Type p53. In addition, overexpression of wild-Type p53 markedly decreased the level of FN expression in p53-mutant breast cancer cells. To examine the mechanism underlying the relationship between p53 and FN expression, we treated MCF7 breast cancer cells with the tumor promoter TPA (12-O-Tetradecanoylphorbol-13-Acetate). Our results showed that basal FN expression was increased by TPA treatment in a time-dependent manner. In contrast, the level of p53 expression was decreased by TPA treatment. However, the expression of FN and p53 was not altered by TPA in p53-mutant breast cancer cells. Furthermore, the alterations in FN and p53 expression in response to TPA were prevented by a specific MEK inhibitor, UO126. Finally, we demonstrated that TPA triggers degradation of p53 through the proteasomal pathway in MCF7 cells. TPA-induced FN expression was decreased by the proteasome inhibitor MG132. Under the same condition, p53 protein expression, but not mRNA expression, was reversed by MG132. Taken together, our data demonstrate that the level of FN expression is associated with the status and expression of p53 in breast cancer cells.

KW - ERK

KW - Fibronectin

KW - MEK

KW - P53

KW - Proteasomal degradation

UR - http://www.scopus.com/inward/record.url?scp=85029809232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029809232&partnerID=8YFLogxK

U2 - 10.3892/or.2017.5860

DO - 10.3892/or.2017.5860

M3 - Article

C2 - 28765903

AN - SCOPUS:85029809232

VL - 38

SP - 2551

EP - 2557

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -